Mean PFT values at baseline and the end of the trial
| PFT . | AERx . | . | SC . | . | |||
|---|---|---|---|---|---|---|---|
| . | Baseline . | End of trial . | Baseline . | End of trial . | |||
| n | 54 | 50 | 53 | 48 | |||
| FVC | 95.6 ± 12.7 | 93.9 ± 14.2 | 97.2 ± 13.7 | 95.3 ± 14.4 | |||
| Change from baseline analysis | −2.3 ± 5.7 | −2.4 ± 5.8 | |||||
| AERx minus SC: 0.19 [−2.0 to 2.43], P = 0.86 | |||||||
| n | 54 | 50 | 53 | 48 | |||
| FEV1 | 97.6 ± 13.2 | 95.1 ± 14.4 | 96.2 ± 12.2 | 93.4 ± 13.9 | |||
| Change from baseline analysis | −3.2 ± 5.7 | −3.5 ± 5.8 | |||||
| AERx minus SC: 0.36 [−1.9 to 2.62], P = 0.75 | |||||||
| n | 54 | 50 | 53 | 48 | |||
| FEV1% | 104.6 ± 8.6 | 103.9 ± 9.6 | 101.1 ± 8.3 | 100.1 ± 10.0 | |||
| Change from baseline analysis | −1.1 ± 5.4 | −2.1 ± 5.8 | |||||
| AERx minus SC: 1.07 [−1.1 to 3.28], P = 0.34 | |||||||
| n | 51 | 49 | 53 | 48 | |||
| TLC | 94.5 ± 13.4 | 93.4 ± 13.2 | 96.1 ± 12.9 | 96.1 ± 13.8 | |||
| Change from baseline analysis | −1.9 ± 6.0 | −0.86 ± 6.0 | |||||
| AERx minus SC: −1.08 [−3.5 to 1.30], P = 0.37 | |||||||
| n | 53 | 49 | 52 | 48 | |||
| DLCO | 91.3 ± 16.8 | 90.8 ± 18.4 | 93.6 ± 16.7 | 94.3 ± 16.5 | |||
| Change from baseline analysis | −2.0 ± 9.1 | −1.1 ± 8.9 | |||||
| AERx minus SC: −0.97 [−4.5 to 2.52], P = 0.58 | |||||||
| PFT . | AERx . | . | SC . | . | |||
|---|---|---|---|---|---|---|---|
| . | Baseline . | End of trial . | Baseline . | End of trial . | |||
| n | 54 | 50 | 53 | 48 | |||
| FVC | 95.6 ± 12.7 | 93.9 ± 14.2 | 97.2 ± 13.7 | 95.3 ± 14.4 | |||
| Change from baseline analysis | −2.3 ± 5.7 | −2.4 ± 5.8 | |||||
| AERx minus SC: 0.19 [−2.0 to 2.43], P = 0.86 | |||||||
| n | 54 | 50 | 53 | 48 | |||
| FEV1 | 97.6 ± 13.2 | 95.1 ± 14.4 | 96.2 ± 12.2 | 93.4 ± 13.9 | |||
| Change from baseline analysis | −3.2 ± 5.7 | −3.5 ± 5.8 | |||||
| AERx minus SC: 0.36 [−1.9 to 2.62], P = 0.75 | |||||||
| n | 54 | 50 | 53 | 48 | |||
| FEV1% | 104.6 ± 8.6 | 103.9 ± 9.6 | 101.1 ± 8.3 | 100.1 ± 10.0 | |||
| Change from baseline analysis | −1.1 ± 5.4 | −2.1 ± 5.8 | |||||
| AERx minus SC: 1.07 [−1.1 to 3.28], P = 0.34 | |||||||
| n | 51 | 49 | 53 | 48 | |||
| TLC | 94.5 ± 13.4 | 93.4 ± 13.2 | 96.1 ± 12.9 | 96.1 ± 13.8 | |||
| Change from baseline analysis | −1.9 ± 6.0 | −0.86 ± 6.0 | |||||
| AERx minus SC: −1.08 [−3.5 to 1.30], P = 0.37 | |||||||
| n | 53 | 49 | 52 | 48 | |||
| DLCO | 91.3 ± 16.8 | 90.8 ± 18.4 | 93.6 ± 16.7 | 94.3 ± 16.5 | |||
| Change from baseline analysis | −2.0 ± 9.1 | −1.1 ± 8.9 | |||||
| AERx minus SC: −0.97 [−4.5 to 2.52], P = 0.58 | |||||||
Data are means ± SD unless otherwise indicated. The calculated mean difference of change from baseline after 12 weeks of treatment, the 95% CI, and P values are based on an ANOVA. The PFT values measured were as follows: forced vital capacity (FVC), forced expiratory volume in first second (FEV1), forced expiratory volume in first second/FVC (FEV%), total lung capacity (TLC), and diffusion capacity for carbon monoxide (DLCO). The unit for all these values was percent of predicted normal value.